venBio Global Strategic — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases.
BiotechBoston, US
Gregory L Verdine(Executive Officer, Director)Mathai Mammen(CEO, President and Chairman)
Board seatCorey S. Goodman· per SEC Form D · $178M raise · filed Dec 2022
Co-investorsCatalio Capital Management, LPHorizons VenturesGV (Google Ventures)
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D · $167.9M raise · filed Sep 2022
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVersant Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.